Suppr超能文献

用于癌症检测的自身抗体生物标志物。

Autoantibody biomarkers in the detection of cancer.

作者信息

Cho-Chung Yoon S

机构信息

Cellular Biochemistry Section, Basic Research Laboratory, CCR, National Cancer Institute, Building 10, Room 5B05, 9000 Rockville Pike, Bethesda, MD 20892-1750, USA.

出版信息

Biochim Biophys Acta. 2006 Jun;1762(6):587-91. doi: 10.1016/j.bbadis.2006.04.001. Epub 2006 Apr 19.

Abstract

By definition, tumor biomarkers are selective molecules that can distinguish between patients with cancer and controls. Serum tumor markers have been the most widely used approach for cancer detection. However, the limitations of these markers, which are based on the measurement of tumor antigens, preclude their general use in cancer screening and diagnosis. Here we give an overview of recent cancer biomarker developments based on the detection of autoantibodies produced against tumor antigens in patients' sera. This new detection method can measure the autoantibodies for a spectrum of tumor antigens in a single assay, with sensitivity and specificity exceeding those obtained using the conventional antigen determination method. Autoantibodies against serum cancer biomarkers offer a novel technology for cancer detection.

摘要

根据定义,肿瘤生物标志物是能够区分癌症患者和对照人群的选择性分子。血清肿瘤标志物一直是癌症检测中使用最广泛的方法。然而,这些基于肿瘤抗原测量的标志物存在局限性,阻碍了它们在癌症筛查和诊断中的普遍应用。在此,我们概述了基于检测患者血清中针对肿瘤抗原产生的自身抗体的癌症生物标志物的最新进展。这种新的检测方法能够在一次检测中测量一系列肿瘤抗原的自身抗体,其灵敏度和特异性超过了使用传统抗原测定方法所获得的结果。针对血清癌症生物标志物的自身抗体为癌症检测提供了一种新技术。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验